Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice

Journal of Controlled Release

Volumn 114, Issue 3, 2006, Pages 381-388

  Kim, Won Jong ^a   Yockman, James W ^a   Jeong, Ji Hoon ^a   Christensen, Lane V ^a   Lee, Minhyung ^b   Kim, Yong Hee ^b   Kim, Sung Wan ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Hanyang University   (South Korea)

Author keywords

Anti angiogenesis; Soluble Flt 1; Systemic injection; Targeted gene delivery; Tumor therapy

Indexed keywords

ANGIOGRAPHY; BIODIVERSITY; BIOLOGICAL ORGANS; COMPLEXATION; DRUG THERAPY; GENETIC ENGINEERING;

ANTI ANGIOGENESIS; SOLUBLE FLT-1; SYSTEMIC INJECTION; TARGETED GENE DELIVERY; TUMOR THERAPY;

TUMORS;

ARGINYLGLYCYLASPARTIC ACID; GREEN FLUORESCENT PROTEIN; MACROGOL; POLYETHYLENEIMINE; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; DRUG CARRIERS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33748160118     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.05.029     Document Type: Article

References (41)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 277 (1997) 48-50
3. Griffioen A.W., and Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52 (2000) 237-268
4. Folkman J., and Shing Y. Angiogenesis. J. Biol. Chem. 267 (1992) 10931-10934
5. Korpelainen E.I., and Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell Biol. 10 (1998) 159-164
6. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 4-25
7. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
8. Thomas K.A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271 (1996) 603-606
9. Millauer B., Shawver L.K., Plate K.H., Risau W., and Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 (1994) 576-579
10. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10705-10709
11. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226 (1996) 324-328
12. Goldman C.K., Kendall R.L., Cabrera G., Soroceanu L., Heike Y., Gillespie G.Y., Siegal G.P., Mao X., Bett A.J., Huckle W.R., Thomas K.A., and Curiel D.T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8795-8800
13. Kong H.L., Hecht D., Song W., Kovesdi I., Hackett N.R., Yayon A., and Crystal R.G. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum. Gene Ther. 9 (1998) 823-833
14. Takayama K., Ueno H., Nakanishi Y., Sakamoto T., Inoue K., Shimizu K., Oohashi H., and Hara N. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 60 (2000) 2169-2177
15. Mori A., Arii S., Furutani M., Mizumoto M., Uchida S., Furuyama H., Kondo Y., Gorrin-Rivas M.J., Furumoto K., Kaneda Y., and Imamura M. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes. Gene Ther. 7 (2000) 1027-1033
16. Suh W., Han S.-o., Yu L., and Kim S.W. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol. Ther. 6 (2002) 664-672
17. Kim W.J., Yockman J.W., Lee M., Jeong J.H., Kim Y.-H., and Kim S.W. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J. Control. Release 106 (2005) 224-234
18. Fenske D.B., MacLachlan I., and Cullis P.R. Long-circulating vectors for the systemic delivery of genes. Curr. Opin. Mol. Ther. 3 (2001) 153-158
19. Dash P.R., Read M.L., Barrett L.B., Wolfert M.A., and Seymour L.W. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 6 (1999) 643-650
20. Hart S.L., Knight A.M., Harbottle R.P., Mistry A., Hunger H.D., Cutler D.F., Williamson R., and Coutelle C. Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J. Biol. Chem. 269 (1994) 12468-12474
21. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
22. Zitzmann S., Ehemann V., and Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 62 (2002) 5139-5143
23. Ferrara N., Houck K., Jakeman L., and Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13 (1992) 18-32
24. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
25. Shibuya M. Role of VEGF-flt-1 receptor system in normal and tumor angiogenesis. Adv. Cancer Res. 67 (1995) 281-316
26. Yoshimura I., Mizuguchi Y., Miyajima A., Asano T., Tadakuma T., and Hayakawa M. Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I. J. Urol. 171 (2004) 2467-2470
27. Ye C., Feng C., Wang S., Wang K.Z., Huang N., Liu X., Lin Y., and Li M. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 145 (2004) 817-822
28. Heidenreich R., Machein M., Nicolaus A., Hilbig A., Wild C., Clauss M., Plate K.H., and Breier G. Inhibition of solid tumor growth by gene transfer of VEGF receptor-1 mutants. Int. J. Cancer 111 (2004) 348-357
29. Hoshida T., Sunamura M., Duda D.G., Egawa S., Miyazaki S., Shineha R., Hamada H., Ohtani H., Satomi S., and Matsuno S. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 25 (2002) 111-121
30. Kou B., Li Y., Zhang L., Zhu G., Wang X., Li Y., Xia J., and Shi Y. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-1 fragment. Exp. Mol. Pathol. 76 (2004) 129-137
31. Ohlfest J.R., Demorest Z.L., Motooka Y., Vengco I., Oh S., Chen E., Scappaticci F.A., Saplis R.J., Ekker S.C., Low W.C., Freese A.B., and Largaespada D.A. Combinational antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol. Ther. 12 (2005) 778-788
32. Hosseinkhani H., and Tabata Y. PEGylation enhances tumor targeting of plasmid DNA by an artificial cationized protein with repeated RGD sequences, Pronectin. J. Control. Release 97 (2004) 157-171
33. Svahn M.G., Salih G., Simonson E.O., Smith C.I., and Branden L.J. Protease-induced release of functional peptides from bioplexes. J. Control. Release 98 (2004) 169-177
34. Veronese F.M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A., Ford J., Wu G., Kneller S., Davies J., and Duncan R. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug. Chem. 16 (2005) 775-784
35. Xiong X.B., Huang Y., Lu W.L., Zhang H., Zhang X., and Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm. Res. 22 (2005) 933-939
36. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., and Zhang Q. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J. Pharm. Sci. 94 (2005) 1782-1793
37. Iinuma H., Maruyama K., Okinaga K., Sasaki K., Sekine T., Ishida O., Ogiwara N., Johkura K., and Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 99 (2002) 130-137
38. Turk M.J., Waters D.J., and Low P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213 (2004) 165-172
39. Bikram M., Lee M., Chang C.W., Janat-Amsbury M.M., Kern S.E., and Kim S.W. Long-circulating DNA-complexed biodegradable multiblock copolymers for gene delivery: degradation profiles and evidence of dysopsonization. J. Control. Release 103 (2005) 221-233
40. Mathot F., van Beijsterveldt L., Preat V., Brewster M., and Arien A. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J. Control. Release 111 (2006) 47-55
41. Schraa A.J., Kok R.J., Berendsen A.D., Moorlag H.E., Bos E.J., Meijer D.K., de Leij L.F., and Molema G. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J. Control. Release 83 (2002) 241-251